Frontier Biotechnologies Gains NMPA Approval for Albuvirtide Phase II Study
Nanjing-based Frontier Biotechnologies Inc. has announced receiving approval from the National Medical Products Administration (NMPA)...
HIV / AIDS care
Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...
Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents
GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...
Frontier Biotechnologies Inc. Gets NMPA Approval for Phase II Study of Albuvirtide as HIV Therapy
Nanjing-based Frontier Biotechnologies Inc. (SHA: 688221) has received approval from the National Medical Products Administration...
Jiangsu Aidea Pharmaceutical Secures NMPA Approval for Expanded Indication of Fubangde in HIV Treatment
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...
Gilead’s Lenacapavir Shows 100% Efficacy in Phase III HIV PrEP Study
Gilead Sciences Inc. (NASDAQ: GILD), a U.S. biopharmaceutical company, has announced topline results from the...
Jiangsu Aidea Pharmaceutical Gets Green Light from NMPA for AINUOVirine APIs
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a biopharmaceutical company based in China, has announced...
ViiV Healthcare’s HIV-PreP Therapy Approved by China’s NMPA, Offers Alternative to Daily Medication
GlaxoSmithKline’s (GSK; NYSE: GSK) subsidiary, ViiV Healthcare, has announced that it has received marketing approvals...
GSK’s ViiV Healthcare Expands Dovato Indication to Include Adolescents with HIV-1 Infection
GlaxoSmithKline’s (GSK; NYSE: GSK) ViiV Healthcare has received an indication extension from the US Food...
Gilead and MSD Report Positive Interim Data for Once-Weekly HIV Treatment in Phase II Trial
Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co., Inc., known as MSD (NYSE: MRK),...
ViiV Healthcare Presents Phase I Data for Ultra-Long-Acting Cabotegravir in HIV Treatment and Prevention
GlaxoSmithKline (GSK; NYSE: GSK) unit ViiV Healthcare has presented Phase I results for an ultra-long-acting...
Gilead’s Biktarvy Receives FDA Approval for Expanded HIV Treatment Indication
Gilead (NASDAQ: GILD), a leading US pharmaceutical company, has been granted an indication extension approval...
Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline
Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with...
Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle
Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining...
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth...
Gilead’s Descovy Receives Additional Indication Approval from China’s NMPA for HIV-1 PrEP
Gilead Sciences, Inc. (NASDAQ: GILD), a major player in the pharmaceutical industry in the U.S.,...
Aidea Pharmaceutical Receives NMPA Approval to Clinically Test HIV-1 Treatment ACC017
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, has announced...
Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...
Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook
Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...
GSK’s ViiV Healthcare Secures NMPA Approval for Vocabria in HIV-1 Treatment
UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that its HIV joint venture, ViiV...